Sign Out
Number of accidental overdoses reports of octreotide in adults and children has been limited.
In adults, the doses ranged from 2,400-6,000 microgram/day administered by continuous infusion (100-250 microgram/hour) or subcutaneously (1,500 micrograms, 3 times/day). The adverse events reported were arrhythmia, hypotension, cardiac arrest, brain hypoxia, pancreatitis, hepatitis steatosis, diarrhea, weakness, lethargy, weight loss, hepatomegaly, and lactic acidosis.
In children, the doses ranged from 50-3,000 microgram/day administered by continuous infusion (2.1-500 microgram/hour) or subcutaneously (50-100 microgram). The only adverse event reported was mild hyperglycemia.
No unexpected adverse events have been reported in cancer patients receiving Octreotide at doses of 3,000-30,000 microgram/day in divided doses subcutaneously.
The management of overdose is symptomatic.
